ClinicalTrials.Veeva

Menu

Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease

University of Delaware logo

University of Delaware

Status and phase

Unknown
Phase 4

Conditions

Chronic Kidney Disease

Treatments

Dietary Supplement: Placebo
Dietary Supplement: MitoQ

Study type

Interventional

Funder types

Other

Identifiers

NCT02364648
680076-2

Details and patient eligibility

About

The purpose of this study is to examine the effect of mitochondria derived oxidative stress on vascular function in patients with moderate to severe Chronic Kidney Disease.

Full description

Chronic Kidney Disease (CKD) patients are at increased risk of cardiovascular disease. Endothelial dysfunction, characterized by a reduced bioavailability in nitric oxide, is an independent predictor of cardiovascular disease in CKD. Increased oxidative stress is a potential cause of endothelial dysfunction in this patient cohort. This study investigates the role that mitochondrial derived oxidative stress plays in CKD related vascular dysfunction. In a controlled, double blinded trial, Stage 3-5 CKD patients will be randomly assigned to receive a 4 week daily dose of a mitochondria targeted antioxidant (MitoQ) or a placebo.

Enrollment

24 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stage 3 - 5 Chronic Kidney Disease

Exclusion criteria

  • History of cardiovascular disease;
  • Current pregnancy;
  • Uncontrolled hypertension;
  • Uncontrolled hyperlipidemia;
  • Current hormone replacement therapy;
  • Current use of tobacco products;
  • Elevated liver enzymes;
  • Current autoimmune disease;
  • Daily use of of antioxidants >300mg

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

24 participants in 2 patient groups, including a placebo group

MitoQ
Experimental group
Description:
4 week 20mg oral daily dose of MitoQ
Treatment:
Dietary Supplement: MitoQ
Placebo
Placebo Comparator group
Description:
4 week 20mg oral daily placebo
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Danielle L Kirkman, PhD; David G Edwards, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems